| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_129e393582e6bdf4029baf2206522f45 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C231-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-435 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1751
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate |
2015-09-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d0a3619f6a7adc8507f2c45da2fb6cb6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6bc93a81e2adf3099157120f7b16889d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_99e765335600708f272d249a9a922a65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_141bcfcd83882f55ffc0b8ecf6c4c886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_762c2a37964d8142678d26a6d1e75a9d |
| publicationDate |
2017-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3189847-A1 |
| titleOfInvention |
Therapeutic or prophylactic agent for itching skin diseases |
| abstract |
Disclosed is a novel means which enables treatment or prophylaxis of pruritic dermatoses such as atopic dermatitis. As a result of intensive study, the present inventors discovered that an antimicrobial peptide LL-37 has an action to promote expression of a nerve repulsion factor Sema3A. LL-37 is a peptide composed of the C-terminal 37 residues of human cathelicidin hCAP18. Use of this antimicrobial peptide enables normalization of expression of axon guidance molecules such as nerve repulsion factor in lesions of pruritic dermatoses including atopic dermatitis and xeroderma, and thus enables alleviation of pruritus and amelioration of skin lesions. |
| priorityDate |
2014-09-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |